{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:40:40Z","timestamp":1782783640205,"version":"3.54.5"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018625","name":"Science and Technology Innovation Plan Of Shanghai Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background and aim:<\/jats:bold> Fuzheng Huayu Recipe (FZHY) is a Chinese patent medicine (approval No. Z20020074) included in the national medical insurance catalogue, which is mainly used for anti-hepatic fibrosis treatment of hepatitis B virus (HBV) induced liver fibrosis and liver cirrhosis. In clinical practice, we discovered that FZHY might also have a direct anti-HBV effect on inhibiting HBeAg production, but the mechanism underlying was unclear. This study aimed to clarify the molecular mechanism of the inhibition effect of FZHY on HBeAg production.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The decrease degree of serum HBeAg titer in FZHY + entecavir (ETV) group patients were analyzed through clinical data. C57BL\/6N-Tg (1.28HBV)\/Vst HBV transgenic mice were used for <jats:italic>in vivo<\/jats:italic> experiments. HepG2. 2.15 cells (wild-type HBV replication cells) were used for <jats:italic>in vitro<\/jats:italic> experiments.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The clinical study results showed that the decrease degree of serum HBeAg titer in FZHY+ETV group was significantly higher than that in ETV group after 48 weeks treatment. <jats:italic>In vivo<\/jats:italic> experiments results showed that FZHY could significantly reduce the serum HBeAg titer in HBV transgenic mice, and promote HBeAg seroconversion. <jats:italic>In vitro<\/jats:italic> experiments results showed that FZHY could reduce HBeAg titer dependently, but it did not significantly inhibit the expression of HBsAg and HBV-DNA. Further cell experiments <jats:italic>in vitro<\/jats:italic> discovered that TOMM34 might be the key target for FZHY to inhibit HBeAg production. The subsequent pharmacological screening experiment of 20 active compounds in FZHY showed that quercetin, baicalin and cordycepin could promote the expression of TOMM34 gene and reduce the production of HBeAg.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> In conclusion, FZHY and its active compounds quercetin, baicalin and cordycepin could inhibit HBeAg production by promoting the expression of TOMM34 gene in HBV-infected hepatocytes.<\/jats:p>","DOI":"10.3389\/fphar.2022.907921","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T09:55:12Z","timestamp":1664186112000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Fuzheng Huayu Recipe and its active compounds inhibited HBeAg production by promoting TOMM34 gene expression in HBV-infected hepatocytes"],"prefix":"10.3389","volume":"13","author":[{"given":"Lu","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10549-012-2249-4","article-title":"TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome","volume":"136","author":"Aleskandarany","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"B2","first-page":"553","article-title":"Induction of T helper cell type 1 response and elimination of HBeAg during treatment with IL-12 in a patient with therapy-refractory chronic Hepatitis B","volume":"48","author":"Barth","year":"2001","journal-title":"Hepatogastroenterology."},{"key":"B3","first-page":"50","article-title":"Interactions between traditional Chinese medicines and Western therapeutics","volume":"13","author":"Chan","year":"2010","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"B4","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3760\/cma.j.issn.1000-6680.2009.11.010","article-title":"Five-year follow-up study on Hepatitis B e antigen positive chronic Hepatitis B virus carriers","volume":"27","author":"Deng","year":"2009","journal-title":"Zhong. Hua. Chuan. Ran. Bing. Za. Zhi."},{"key":"B5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: Management of chronic Hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1158\/1535-7163.MCT-17-0104","article-title":"Genomic and molecular screenings identify different mechanisms for acquired resistance to MET inhibitors in lung cancer cells","volume":"16","author":"Gimenez-Xavier","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3760\/cma.j.issn.1007-3418.2015.12.002","article-title":"The guideline of prevention and treatment for chronic Hepatitis B: a 2015 update","volume":"23","author":"Hou","year":"2015","journal-title":"Zhonghua. Gan. Zang. Bing. Za. Zhi."},{"key":"B8","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/hep.21758","article-title":"Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic Hepatitis B Chinese patients","volume":"46","author":"Hui","year":"2007","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3349\/ymj.1993.34.2.158","article-title":"Mutations in the pre-core region of Hepatitis B virus DNA in patients with chronic liver diseases","volume":"34","author":"Kim","year":"1993","journal-title":"Yonsei Med. J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1046\/j.1365-2893.1999.00189.x","article-title":"The core promoter of Hepatitis B virus","volume":"6","author":"Kramvis","year":"1999","journal-title":"J. Viral Hepat."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1002\/hep.23346","article-title":"Severe lactic acidosis during treatment of chronic Hepatitis B with entecavir in patients with impaired liver function","volume":"50","author":"Lange","year":"2009","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.3969\/j.issn.1008-8849.2018.18.025","article-title":"Effect of ursodeoxycholic acid combined with Fuzheng Huayu Capsule on HBeAg positive Hepatitis B cirrhosis patients with high viral load and its effects on liver fibrosis and inflammatory factors","volume":"27","author":"Li","year":"2018","journal-title":"Xian. Dai. Zhong. Xi. Yi. Jie. He. Za. Zhi."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic Hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jhep.2006.08.021","article-title":"Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma","volume":"46","author":"Lin","year":"2007","journal-title":"J. Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/hep.28594","article-title":"Hepatitis B e antigen and its precursors promote the progress of hepatocellular carcinoma by interacting with NUMB and decreasing p53 activity","volume":"64","author":"Liu","year":"2016","journal-title":"Hepatology"},{"key":"B16","first-page":"6","volume-title":"The study on the screening and mechanism of genes regulating HBV replication in hepatocytes of patients with chronic hepatitis B [D]","author":"Liu","year":"2012"},{"key":"B17","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3760\/cma.j.issn.1007-3418.2013.09.006","article-title":"Therapeutic effects of Fuzhenghuayu decoction in a CCl4-induced liver cirrhosis rat model and on hepatic stellate cell activation","volume":"21","author":"Luo","year":"2013","journal-title":"Zhong. Hua. Gan. Zang. Bing. Za. Zhi."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-2005-915644","article-title":"Epidemiology and natural history of Hepatitis B","volume":"25","author":"McMahon","year":"2005","journal-title":"Semin. Liver Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1006\/viro.2000.0391","article-title":"H-2(d) mice born to and reared by HBeAg-transgenic mothers do not develop T cell tolerance toward the Hepatitis B virus core gene products","volume":"273","author":"Merkle","year":"2000","journal-title":"Virology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1089\/dna.1997.16.1067","article-title":"hTom34: a novel translocase for the import of proteins into human mitochondria","volume":"16","author":"Nuttall","year":"1997","journal-title":"DNA Cell Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3892\/ijo.29.2.381","article-title":"Identification of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug target","volume":"29","author":"Shimokawa","year":"2006","journal-title":"Int. J. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S2468-1253(20)30307-1","article-title":"Estimating the proportion of people with chronic Hepatitis B virus infection eligible for Hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis","volume":"6","author":"Tan","year":"2021","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.clinbiochem.2018.12.001","article-title":"Overexpression of heat shock protein HSP90AA1 and translocase of the outer mitochondrial membrane TOM34 in HCV-induced hepatocellular carcinoma: A pilot study","volume":"63","author":"Toraih","year":"2019","journal-title":"Clin. Biochem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/ptr.6009","article-title":"Fuzheng Huayu capsule as an adjuvant treatment for HBV-related cirrhosis: A systematic review and meta-analysis","volume":"32","author":"Wang","year":"2018","journal-title":"Phytother. Res."},{"key":"B25","unstructured":"2021"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e499","DOI":"10.1111\/j.1365-2893.2011.01484.x","article-title":"The Hepatitis B e antigen suppresses IL-1\u03b2-mediated NF-\u03baB activation in hepatocytes","volume":"18","author":"Wilson","year":"2011","journal-title":"J. Viral Hepat."},{"key":"B27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-981-10-5765-6_2","article-title":"Hepatitis B virus-associated hepatocellular carcinoma","volume":"1018","author":"Xie","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s12072-015-9661-x","article-title":"Advances in therapeutics for chronic Hepatitis B","volume":"10","author":"Yang","year":"2016","journal-title":"Hepatol. Int."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1093\/oxfordjournals.aje.a009060","article-title":"Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic Hepatitis B virus carriers","volume":"145","author":"Yu","year":"1997","journal-title":"Am. J. Epidemiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3969\/j.issn.1005-0264.2018.03.007","article-title":"Analysis on the therapeutic effect of nucleoside antiviral drugs combined with Fuzheng Huayu capsule for treating HBeAg-positive HBV infection decompensated cirrhosis patients","volume":"28","author":"Zhan","year":"2018","journal-title":"Zhong. Xi. Yi. Jie. He. Gan. Bing. Za. Zhi."},{"key":"B31","doi-asserted-by":"publisher","first-page":"8591892","DOI":"10.1155\/2020\/8591892","article-title":"Fuzheng Huayu Recipe prevented and treated CCl4-induced mice liver fibrosis through regulating polarization and chemotaxis of intrahepatic macrophages via CCL2 and CX3CL1","volume":"2020","author":"Zhang","year":"2020","journal-title":"Evid. Based. Complement. Altern. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"587479","DOI":"10.3389\/fonc.2021.587479","article-title":"Identification of mitochondrial-related prognostic biomarkers associated with primary bile acid biosynthesis and tumor microenvironment of hepatocellular carcinoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.907921\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T13:08:40Z","timestamp":1664370520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.907921\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":32,"alternative-id":["10.3389\/fphar.2022.907921"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.907921","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,26]]},"article-number":"907921"}}